XTL Biopharmaceuticals Receives Nasdaq Notification for Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals received a notification from Nasdaq that the company does not meet the continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity. The company has 45 calendar days to submit a plan to regain compliance. Although XTL intends to use all reasonable efforts to achieve compliance, there can be no assurance that the company will be able to regain compliance with Nasdaq's continued listing requirements.